Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2022-01-05 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
South Korea HERVaxx Patent Grant 2 pages 89.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited regarding the granting of a patent in South Korea for their HER-Vaxx immunotherapy. It discusses the patent details, market significance, and clinical trial plans. There is no financial data, no mention of financial results, no regulatory certifications, or detailed report content. The document is a corporate announcement about intellectual property and clinical development milestones. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. The content is best classified as a general regulatory announcement or corporate update that does not fit other specific categories, thus falling under Regulatory Filings (RNS). The document length is under 5,000 characters, but it is not announcing the publication of a report, so it is not RPA. Therefore, the best classification is Regulatory Filings (RNS).
2022-01-05 English
Imugene Receives $6.54 million R&D Tax Incentive 2 pages 82.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited regarding the receipt of a $6.54 million R&D tax incentive for the financial year ended 30 June 2021. It is a short announcement (3006 characters) that informs about a specific financial event (receipt of government R&D tax refund) rather than a full financial report or detailed analysis. There is no detailed financial data, management discussion, or comprehensive reporting. The document serves as a regulatory announcement to inform shareholders and the market about this funding event. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-01-05 English
Imugene adds industry leaders to senior management team 2 pages 80.8KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 4 January 2022 from Imugene Limited. It announces the appointment of two senior management team members, Ursula McCurry and Dr Nimali Withana, detailing their backgrounds and roles. There is no financial data, no discussion of financial results, no regulatory filings, no voting results, no legal proceedings, and no mention of any report publication. The content focuses solely on management changes. Therefore, this document fits the category of Board/Management Information (MANG). The document length is about 5,014 characters, which is consistent with a typical announcement rather than a full report.
2022-01-03 English
Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx 2 pages 91.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited about the completion of Phase 1a monotherapy dose escalation of their immunotherapy PD1-Vaxx. It discusses clinical trial progress, safety, early efficacy signals, and plans for the next phase of the trial. There are no financial statements, detailed financial analysis, or comprehensive report data. The document is a clinical trial update and company announcement rather than a financial report or regulatory filing. It is not a full annual or interim report, nor an earnings release. It is a corporate announcement about clinical development progress, which fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-01-03 English
Application for quotation of securities - IMU 8 pages 32.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Application for quotation of +securities' and details the issuance and quotation of securities resulting from options exercised or convertible securities converted. It includes specifics such as the number of securities, issue dates, and whether the securities are cash consideration or issued under employee incentive schemes. The document is an announcement related to the quotation of securities on the ASX (Australian Securities Exchange). It does not contain financial statements, management discussion, or audit information. It is not a report but an official announcement regarding capital changes due to securities issuance and quotation. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length (8942 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2021-12-22 English
Notification regarding unquoted securities - IMU 9 pages 32.2KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of Issue, Conversion or Payment up of Unquoted Equity Securities' and details the issuance of unquoted options under an employee incentive scheme by Imugene Limited. It includes specifics such as the number of securities issued, issue date, security descriptions, and references to ASX listing rules. The content focuses on the announcement of new securities issued, not on financial results, management changes, or other report types. The document length is 9166 characters, which is substantial and contains detailed issuance information rather than a brief announcement or a report publication notice. Therefore, this fits the category of a Share Issue/Capital Change announcement.
2021-12-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.